Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

411
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
411

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

A FRET Aptasensor Based on N-CQDs for Detection of Cardiac Troponin I in Acute Myocardial Infarction Diagnosis.

International journal of nanomedicine·2026
Same author

RHINO: An Integrative Multi-Omics Framework Linking Circadian Physiology to Precision Medicine.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

A Bayesian Adaptive Marker-Stratified Design for Phase II Clinical Trials Using Calibrated Spike-and-Slab priors.

Statistics in biopharmaceutical research·2026
Same author

An Adaptive Biomarker-based Umbrella Trial Design Using Bayesian Latent Class Model.

Statistics in biopharmaceutical research·2026
Same author

Histone deacetylase enzyme activity is not the universal anticancer target of HDAC inhibitors.

Signal transduction and targeted therapy·2026
Same author

Modeling context-dependent RNA splicing by deep learning.

Nature computational science·2026

相关实验视频

Updated: May 16, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.4K

一个没有模型的I/II期剂量优化设计,用于免疫疗法试验.

Yingjie Qiu1, Mengyi Lu2, Yan Han3

  • 1Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, TX, USA.

Statistical methods in medical research
|May 15, 2025
PubMed
概括

我们开发了一个新的,无模型的临床试验设计,称为UFO设计,以优化免疫疗法剂量. 这种方法有效地模拟了毒性,疗效和免疫反应,以获得更好的治疗结果.

关键词:
临床试验I/II期临床试验可接受的集合.延迟的结果延迟的结果剂量优化剂量优化免疫疗法 免疫疗法同位素回归的同位素回归没有模特免费的模型.公用事业公用事业公司

更多相关视频

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
08:17

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

14.2K
Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

3.0K

相关实验视频

Last Updated: May 16, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.4K
A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
08:17

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

14.2K
Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

3.0K

科学领域:

  • 临床试验 临床试验
  • 免疫治疗是一种免疫疗法.
  • 生物统计学 生物统计学

背景情况:

  • 优化免疫疗法剂量对于最大限度地提高疗效,同时最大限度地降低毒性至关重要.
  • 现有的临床试验设计通常依赖于复杂的参数模型,限制透明度和效率.
  • 联合建模多种结果,如毒性,疗效和免疫反应是具有挑战性的,但对于免疫疗法剂量优化至关重要.

研究的目的:

  • 引入一种新的,无模型的I/II期临床试验设计 (UFO设计) 以优化免疫疗法剂量.
  • 通过利用毒性,疗效和免疫反应之间的相关性,实现跨剂量水平的有效信息共享.
  • 扩展UFO设计以适应延迟结果数据,并证明其有利的操作特性.

主要方法:

  • 开发了一种无模型的临床试验设计方法,称为UFO设计.
  • 利用了毒性,疗效和免疫反应结果之间的固有相关性.
  • 整合了受约束的剂量结果排序,以促进信息共享.
  • 扩展了设计以处理延迟结果.

主要成果:

  • 无人机设计证明了临床实施的效率和透明度.
  • 模拟研究显示,拟议的设计具有有利的操作特性.
  • 无模型方法通过联合建模多个结果,有效地优化免疫疗法剂量.

结论:

  • UFO设计提供了一种实用且有效的无模型策略,用于优化临床试验中的免疫疗法剂量.
  • 这种方法通过利用结果相关性和剂量-结果约束来提高效率和透明度.
  • 有R Shiny应用程序的可用性有助于在实践中模拟和实施UFO设计.